Randomized Trialvery high evidence
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
The New England journal of medicine·October 24, 2024·PMID 39225278
Why it mattersThis is the first large trial to show a nonsteroidal mineralocorticoid receptor antagonist improves outcomes in heart failure with mildly reduced or preserved ejection fraction, a population with limited proven therapies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled